{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:27:02Z","timestamp":1791224822198,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft (Bonn, Germany)","award":["Lo 274\/11-2"],"award-info":[{"award-number":["Lo 274\/11-2"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ejphar.2014.11.019","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T01:59:29Z","timestamp":1416535169000},"page":"167-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide"],"prefix":"10.1016","volume":"746","author":[{"given":"Kathrin","family":"T\u00f6llner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"R\u00f6mermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.11.019_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2014.11.019_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.106.102491","article-title":"Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays","volume":"320","author":"Baltes","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2014.11.019_bib3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: the multidrug resistance- associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2014.11.019_bib4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00424-006-0054-9","article-title":"Multidrug resistance-associated proteins 3, 4, and 5","volume":"453","author":"Borst","year":"2007","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ejphar.2014.11.019_bib5","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1523\/JNEUROSCI.0633-10.2010","article-title":"Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy","volume":"30","author":"Brandt","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2014.11.019_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00685739","article-title":"Increased cation transport in mdr1-gene-expressing K562 cells","volume":"36","author":"Brismar","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by Organic Anion Transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2014.11.019_bib8","unstructured":"Goda, S., Thorsheim, H. R., Taskar, K. S., Thomas, A. J., and Smith, Q. R. Restricted brain distribution of bumetanide is mediated by active efflux transporters (rat Oatp & OAT3) at the blood\u2013brain barrier. American Association of Pharmaceutical Scientists AAPS 2010.Published Meeting Abstracts. Number SA7187 Ref Type: Abstract; 2010."},{"key":"10.1016\/j.ejphar.2014.11.019_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","article-title":"Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide","volume":"18","author":"Hasegawa","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib10","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.1021\/bi970530g","article-title":"Analysis of ion transport perturbations caused by hu MDR 1 protein overexpression","volume":"36","author":"Hoffman","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2014.11.019_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0005-2760(95)00239-1","article-title":"Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells","volume":"1300","author":"Horz","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2014.11.019_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneuro0883","article-title":"Roles of the cation-chloride cotransporters in neurological disease","volume":"4","author":"Kahle","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrn3819","article-title":"Cation-chloride cotransporters in neuronal development, plasticity and disease","volume":"15","author":"Kaila","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2014.11.019_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2005.09.054","article-title":"Mouse organic anion transporter 2 and 3 (mOAT2\/3[Slc22a7\/8]) mediates the renal transport of bumetanide","volume":"524","author":"Kobayashi","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1602\/neurorx.2.1.73","article-title":"Active efflux across the blood\u2013brain barrier: role of the solute carrier family","volume":"2","author":"Kusuhara","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ejphar.2014.11.019_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3565(25)22038-9","article-title":"Effect of probenecid on the dose\u2013response relationship of bumetanide at steady state","volume":"227","author":"Lau","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2014.11.019_bib17","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1128\/MCB.24.17.7612-7621.2004","article-title":"Mrp4 confers resistance to topotecan and protects the brain from chemotherapy","volume":"24","author":"Leggas","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"L\u00f6scher","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2014.11.019_bib19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for antiepileptic drug discovery and development","volume":"12","author":"L\u00f6scher","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2014.11.019_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","article-title":"Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments","volume":"69","author":"L\u00f6scher","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2014.11.019_bib21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein","volume":"55","author":"Luna-Tort\u00f3s","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2014.11.019_bib22","series-title":"Jasper\u05f3s Basic Mechanisms Of The Epilepsies","first-page":"581","article-title":"Chloride homeostasis and GABA signaling in temporal lobe epilepsy","author":"Miles","year":"2012"},{"key":"10.1016\/j.ejphar.2014.11.019_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-008-9035-6","article-title":"Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid","volume":"10","author":"Morris","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ejphar.2014.11.019_bib24","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1124\/dmd.105.005264","article-title":"Functional characterization of human monocarboxylate transporter 6 (SLC16A5)","volume":"33","author":"Murakami","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2014.11.019_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0773.1977.tb03209.x","article-title":"The pharmacology of bumetanide","volume":"41","author":"Olsen","year":"1977","journal-title":"Acta Pharmacol. Toxicol. (Copenh)"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2014.11.019_bib26","first-page":"S42","article-title":"What we have learned about bumetanide and the concept of multispecific bile acid\/drug transporters from the liver","volume":"24","author":"Petzinger","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","article-title":"Multidrug resistance protein MRP2 contributes to blood\u2013brain barrier function and restricts antiepileptic drug activity","volume":"306","author":"Potschka","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2014.11.019_bib28","unstructured":"Pressler, R., 2014. Bumetanide. Proceedings of the Twelth EILAT Conference on New Antiepileptic Drugs (EILAT XII), August 31\u2013September 3, 2014, Madrid, Spain."},{"key":"10.1016\/j.ejphar.2014.11.019_bib29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.siny.2013.04.005","article-title":"Newly emerging therapies for neonatal seizures","volume":"18","author":"Pressler","year":"2013","journal-title":"Semin. Fetal Neonatal Med."},{"key":"10.1016\/j.ejphar.2014.11.019_bib30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","article-title":"Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures","volume":"55","author":"Puskarjov","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2014.11.019_bib31","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/mol.63.5.1094","article-title":"Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5","volume":"63","author":"Reid","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1081\/DMR-200047984","article-title":"Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5)","volume":"37","author":"Ritter","year":"2005","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejphar.2014.11.019_bib33","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1146\/annurev.pharmtox.44.101802.121444","article-title":"Evaluation of drug\u2013drug interaction in the hepatobiliary and renal transport of drugs","volume":"45","author":"Shitara","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1474-4422(14)70076-6","article-title":"The challenge and promise of anti-epileptic therapy development in animal models","volume":"13","author":"Simonato","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01061766","article-title":"Determinants of bumetanide response in the dog: effect of probenecid","volume":"11","author":"Smith","year":"1983","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejphar.2014.11.019_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.24124","article-title":"A novel prodrug-based strategy to increase effects of bumetanide in epilepsy","volume":"75","author":"T\u00f6llner","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2014.11.019_bib38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/ejn.12424","article-title":"Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy","volume":"39","author":"T\u00f6pfer","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2014.11.019_bib39","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1007\/s11095-007-9453-7","article-title":"Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter","volume":"24","author":"Uchida","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2014.11.019_bib40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood\u2013brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2014.11.019_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.693","article-title":"Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology","volume":"31","author":"VanWert","year":"2010","journal-title":"Biopharm. Drug Dispos."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991400795X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991400795X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:01:32Z","timestamp":1747166492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429991400795X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":41,"alternative-id":["S001429991400795X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.11.019","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}